Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00880217 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 430
- Enrollment target
NCT00880217 is a Phase 2 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 430 participants.
The verdict
NCT00880217, a Phase 2 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 430 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety/tolerability of 3 different dosages of JNJ-31001074 compared with placebo in adult patients with attention-deficit/hyperactivity disorder (ADHD).
Interventions
- DRUG Placebo
- DRUG Atomoxetine 80 mg/d
- DRUG OROS methylphenidate HCl 54 mg/d
- DRUG JNJ-31001074 3 mg/d
- DRUG JNJ-31001074 1 mg/d
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00880217
The ClinicalTrials.gov registry entry for NCT00880217 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00880217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00880217 about?
NCT00880217 is a clinical study titled "A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". The purpose of this study is to evaluate the efficacy and safety/tolerability of 3 different dosages of JNJ-31001074 compared with placebo in adult patients with attention-deficit/hyperactivity disorder (ADHD).
What is the current status of trial NCT00880217?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 430 participants. The study started on 2009-05. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00880217?
The interventions under investigation include: Placebo (DRUG), Atomoxetine 80 mg/d (DRUG), OROS methylphenidate HCl 54 mg/d (DRUG), JNJ-31001074 3 mg/d (DRUG), JNJ-31001074 1 mg/d (DRUG).
Who is sponsoring clinical trial NCT00880217?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.